HZD.L Regulatory News (HZD)

Horizon Discovery Group plc

Horizon Discovery to host CRISPR Screening Webinar: "How gene editing is becoming embedded in drug discovery workflows at an industrial scale"

Cambridge, UK, 07 November 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in the application of gene editing and gene modulation technologies, will host a CRISPR Screening Webinar today for investors and sell-side analysts between 15:00 - 16:00 GMT / 10:00 - 11:00 ET.

The nature of drug discovery is changing as global pharmaceutical and biotech companies face rising R&D costs and diminishing returns. The availability of CRISPR screening has revolutionised the possibilities of scientific insight via the quality and quantity of data that can be generated and now means that gene editing is becoming embedded in drug discovery workflows at an industrial scale.

This webinar will showcase and explain how Horizon is driving the availability and uses of this novel technological solution for pharmaceutical and biotech companies, from both the Group's and customers' perspectives. The session will address this need and will cover Horizon's, and the wider market's, rapid adoption of CRISPR screening and provide an overview of its broad applicability.

Agenda

· Introduction and commercial progress in CRISPR screening

Terry Pizzie (CEO)

· What is CRISPR screening?

Benedict Cross (Head of Functional Genomic Screening)

· Q&A SessionTerry Pizzie and Benedict Cross joined by Richard Vellacott (CFO) and Chris Lowe (Head of Research Operations)

Registration

To register for the webinar please visit https://edge.media-server.com/m6/p/xv7uwm2q or use the dial-in details below. The dial-in details are recommended for those wishing to participate in the Q&A:

Participant local dial-in: +44 (0) 330 336 9128 (UK) and 1 929-477-0324 (US)

Participant freephone dial-in: 0800 358 6377 (UK) and 800-458-4121 (US)

Conference ID: 6275328

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Tel: +44 (0) 1223 655 580

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5701

Email: horizon@consilium-comms.com

About Horizon Discovery Group plc https://www.horizondiscovery.com/

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker HZD